Canosa Stefano, Revelli Alberto, Cimadomo Danilo, Vaiarelli Alberto, Gennarelli Gianluca, Guidetti Daniela, Carosso Andrea Roberto, Rienzi Laura, Ubaldi Filippo Maria, Bongioanni Francesca
IVIRMA Global Research Alliance, Livet, Via Tiziano Vecellio 3, 10126 Turin, Italy.
Gynecology and Obstetrics 2U, Department of Surgical Sciences, S. Anna Hospital, University of Turin, 10126 Turin, Italy.
Life (Basel). 2025 May 31;15(6):899. doi: 10.3390/life15060899.
This study compared the DuoStim protocol with two conventional follicular phase stimulations for vitrified oocyte accumulation in poor-prognosis patients undergoing PGT-A. A retrospective analysis of 112 IVF cycles was conducted, with 66 cycles among patients undergoing DuoStim (DS-Group) and 46 among patients undergoing conventional follicular phase stimulations (DF-Group). The primary outcome was the time to live birth, while secondary outcomes included clinical pregnancy rate, miscarriage rate, live birth rate, and cumulative live birth rate. The final analysis included 66 patients in the DS-Group and 40 in the DF-Group, as 6 women (13%) in the DF-Group discontinued treatment after the first stimulation. Oocyte yield was similar between groups (8.4 ± 3.9 in DS-Group vs. 8.2 ± 4.0 in DF-Group, = 0.80), as was the number of euploid blastocysts (0.9 ± 1.2 vs. 1.1 ± 1.1, = 0.37). The cumulative live birth rate was 22.7% in the DS-Group and 25% in the DF-Group (multivariate odds ratio adjusted for maternal age and male factor: 1.05, = 0.93). The time to live birth was significantly shorter in the DS-Group (81.5 ± 15.5 days) compared to the DF-Group (153.7 ± 78.2 days, < 0.001). DuoStim showed similar efficacy but a shorter time to live birth.
本研究比较了DuoStim方案与两种传统卵泡期刺激方案在接受植入前基因检测（PGT-A）的预后不良患者中用于冻存卵母细胞积累的效果。对112个体外受精周期进行了回顾性分析，其中66个周期为接受DuoStim方案的患者（DS组），46个周期为接受传统卵泡期刺激方案的患者（DF组）。主要结局是活产时间，次要结局包括临床妊娠率、流产率、活产率和累积活产率。最终分析纳入了DS组的66例患者和DF组的40例患者，因为DF组有6名女性（13%）在首次刺激后停止治疗。两组的卵母细胞产量相似（DS组为8.4±3.9，DF组为8.2±4.0，P=0.80），整倍体囊胚数量也相似（分别为0.9±1.2和1.1±1.1，P=0.37）。DS组的累积活产率为22.7%，DF组为25%（根据产妇年龄和男性因素调整后的多变量优势比：1.05，P=0.93）。与DF组（153.7±78.2天）相比，DS组的活产时间显著缩短（81.5±15.5天，P<0.001）。DuoStim方案显示出相似的疗效，但活产时间更短。
